Not Yet RecruitingNot Applicable

Development and Validation of the Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)

United States100 participantsStarted 2026-01

Plain-language summary

Main aim will be to compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: Patients with a Diagnosis of POTS, IST, or vasovagal syncope Exclusion criteria: Patients with comorbid chronic conditions causing significant impairments in quality of life, defined as: * NYHA Class III or IV Heart Failure * COPD GOLD 3 or 4, Group C or D * Any patients with current malignancy not in remission * Any patient with history of Autoimmune disease requiring chronic steroid therapy or immunomodulatory agents: Rheumatoid Arthritis, Lupus, Sarcoidosis, Psoriasis All patients with ESRD requiring hemodialysis All patients with cirrhosis of any origin Any patients with solid organ or bone marrow transplant requiring immunosuppressive therapy

What they're measuring

To develop and validate KCDysQ as a quality of life and symptom severity assessment tool

Timeframe: 3 Months

Trial details

NCT IDNCT06672861

SponsorKansas City Heart Rhythm Research Foundation

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08

Contact for this trial

Donita Atkins

816-651-1969 datkins@kchrf.com

View on ClinicalTrials.gov More Cardiac Dysautonomia trials